Seattle and Vancouver-based Achieve Life Sciences, Inc. (Nasdaq: ACHV) disclosed that the US FDA issued a Complete Response Letter for the New Drug Application for cytisinicline, a plant-derived nicotinic acetylcholine receptor partial agonist under development as a treatment for nicotine dependence in adult smokers. The Achieve Life Sciences cytisinicline CRL does not reflect concerns about clinical efficacy or safety — a distinction that materially narrows the remediation path and supports the company’s stated timeline for resubmission and potential approval in the first half of 2027.
The FDA’s action was driven entirely by current Good Manufacturing Practice deficiencies identified during an inspection of a third-party manufacturing facility named in the NDA, which subsequently received an Official Action Indicated classification. The OAI designation reflected general cGMP matters at the facility unrelated to cytisinicline specifically. The agency also noted that final product labeling had not been completed by the June 20, 2026 Prescription Drug User Fee Act action date.
Achieve had anticipated this outcome as early as April 15, 2026, when it disclosed that an OAI classification had been assigned to the prior manufacturing facility and stated it expected to receive a CRL on or before the PDUFA date. The company had already taken proactive steps by that point, partnering with Adare Pharma Solutions, a US-based contract development and manufacturing organization, as its new primary commercial manufacturing partner.
Cytisinicline is a plant-based alkaloid derived from the golden chain tree with high binding affinity to the α4β2 nicotinic acetylcholine receptor — the same receptor subtype through which nicotine exerts its reinforcing effects. By acting as a partial agonist, it is believed to reduce nicotine craving severity and attenuate the reward associated with nicotine use, supporting cessation in both smokers and e-cigarette users.